TriSalus Life Sciences Announces Publication of Safety and Efficacy Results for a Novel Pressure-Enabled Thyroid Embolization Technique

WESTMINSTER, Colo.--(BUSINESS WIRE)--TriSalus Life Sciences® Inc. (Nasdaq: TLSI) (“TriSalus” or the “Company”), an oncology company integrating novel delivery technology with standard of care therapies to transform treatment for patients with solid tumors, is pleased to announce the publication of clinical data evaluating the use of its proprietary Pressure-Enabled Drug DeliveryTM (PEDDTM) technology in thyroid parenchymal embolization, a new application for the treatment of patients with sympt